A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

NCT00743938 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: BMS-690514
DRUG: Erlotinib

Sponsor

Bristol-Myers Squibb